학술논문

Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis
Document Type
Article
Source
In: Rheumatology (United Kingdom). (Rheumatology (United Kingdom), 1 April 2022, 61(4):1385-1395)
Subject
Language
English
ISSN
14620332
14620324